

CITATION REPORT

List of articles citing

Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention

DOI: 10.1177/0272989x15587005
Medical Decision Making, 2015, 35, 859-71.

Source: <https://exaly.com/paper-pdf/61280584/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
42	A benefit-risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients. <i>Therapeutics and Clinical Risk Management</i> , 2016 , 12, 965-74	2.9	0
41	Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 548-54	6.1	48
40	A threshold analysis assessed the credibility of conclusions from network meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2016 , 80, 68-76	5.7	17
39	Decision support for risk prioritisation of environmental health hazards in a UK city. <i>Environmental Health</i> , 2016 , 15 Suppl 1, 29	6	9
38	Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016 , 19, 125-37	3.3	229
37	Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. <i>Social Science and Medicine</i> , 2017 , 188, 137-156 ^{5.1}	5.1	83
36	Resource Allocation and Priority Setting in Health Care: A Multi-criteria Decision Analysis Problem of Value?. <i>Global Policy</i> , 2017 , 8, 76-83	1.8	28
35	Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis. <i>Value in Health</i> , 2017 , 20, 1394-1402	3.3	4
34	MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1483-1491	2.6	29
33	Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States. <i>Value in Health</i> , 2017 , 20, 132-140	3.3	11
32	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. <i>BMC Medical Informatics and Decision Making</i> , 2017 , 17, 149	3.6	20
31	References. 2018 , 409-445		
30	Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. <i>Oncologist</i> , 2018 , 23, 44-51	5.7	31
29	How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 379-391	2.2	8
28	Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis. <i>Contemporary Clinical Trials</i> , 2018 , 67, 100-108	2.3	4
27	. 2018 ,		98
26	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden.. <i>MDM Policy and Practice</i> , 2018 , 3, 2381468318796218	1.5	2

25	Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. <i>Medical Decision Making</i> , 2019 , 39, 998-1009	2.5	4
24	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. <i>European Journal of Health Economics</i> , 2019 , 20, 891-918	3.6	18
23	A Bayesian approach for individual-level drug benefit-risk assessment. <i>Statistics in Medicine</i> , 2019 , 38, 3040-3052	2.3	1
22	Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. <i>Medical Decision Making</i> , 2019 , 39, 264-277	2.5	7
21	Personalized benefit-risk assessments combining clinical trial and real-world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 443-451	2.6	4
20	Biocatalyzed Synthesis of Statins: A Sustainable Strategy for the Preparation of Valuable Drugs. <i>Catalysts</i> , 2019 , 9, 260	4	23
19	Quantifying Preferences in Drug Benefit-Risk Decisions. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 955-959	6.1	10
18	Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support. <i>Medical Decision Making</i> , 2019 , 39, 239-252	2.5	4
17	Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 31-46	3.4	10
16	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. <i>Social Science and Medicine</i> , 2020 , 246, 112595	5.1	10
15	Extensions of the probabilistic ranking metrics of competing treatments in network meta-analysis to reflect clinically important relative differences on many outcomes. <i>Biometrical Journal</i> , 2020 , 62, 375-385	1.5	7
14	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020 , 40, 830-845	2.5	4
13	Network meta-analysis results against a fictional treatment of average performance: Treatment effects and ranking metric. <i>Research Synthesis Methods</i> , 2021 , 12, 161-175	7.2	0
12	Partial Personalization of Medical Treatment Decisions: Adverse Effects and Possible Solutions. <i>Medical Decision Making</i> , 2022 , 42, 8-16	2.5	
11	Personalization of Medical Treatment Decisions: Simplifying Complex Models while Maintaining Patient Health Outcomes. <i>Medical Decision Making</i> , 2021 , 272989X211037921	2.5	1
10	Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment. <i>Patient</i> , 2021 , 1	3.7	1
9	??? ?? ??? ??????(Multiple Criteria Decision Analysis) ??? ?? ?. <i>The Journal of Health Technology Assessment</i> , 2015 , 3, 75-89	0.1	2
8	BenefitRisk Assessment. 2017 , 105-118		

7	The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA). <i>AboutOpen</i> , 2019 , 6, 78-85	0.3	
6	Introducing the Treatment Hierarchy Question in Network Meta-Analysis.. <i>American Journal of Epidemiology</i> , 2021 ,	3.8	3
5	Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment. <i>Journal of Clinical Epidemiology</i> , 2021 ,	5.7	0
4	Answering complex hierarchy questions in network meta-analysis.. <i>BMC Medical Research Methodology</i> , 2022 , 22, 47	4.7	
3	An analytic network process model for hospital facilities management performance evaluation. <i>Facilities</i> , 2022 , 40, 333-352	2.2	0
2	The complexity underlying treatment rankings: how to use them and what to look at.. <i>BMJ Evidence-Based Medicine</i> , 2022 ,	2.7	0
1	Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. 2023 , 26, 449-460		0